Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease

被引：11

作者：

Kinsella, Francesca A. M. ^{[1
,2
]}

Inman, Charlotte F. ^{[1
]}

Gudger, Amy ^{[3
]}

Ghan, Yuen T. ^{[1
]}

Murray, Duncan J. ^{[1
]}

Zuo, Jianmin ^{[1
]}

McIlroy, Graham ^{[2
]}

Nagra, Sandeep ^{[2
]}

Nunnick, Jane ^{[2
]}

Holder, Kathy ^{[3
]}

Wall, Kerry ^{[4
]}

Griffiths, Mike ^{[1
,4
]}

Craddock, Charles ^{[2
]}

Nikolousis, Emmanouil ^{[3
]}

Moss, Paul ^{[1
,2
]}

Malladi, Ram ^{[1
,2
]}

机构：

[1] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England

[2] Queen Elizabeth NHS Fdn Trust, Ctr Clin Haematol, Birmingham, W Midlands, England

[3] Heart England NHS Fdn Trust, Heartlands Hosp, Birmingham, W Midlands, England

[4] Birmingham Womens NHS Fdn Trust, West Midlands Reg Genet Lab, Birmingham, W Midlands, England

来源：

LEUKEMIA RESEARCH | 2019年 / 83卷

基金：

英国医学研究理事会;

关键词：

Chimerism; AML; Allogeneic-HSCT; Relapse; VERSUS-HOST-DISEASE; DONOR LYMPHOCYTE INFUSIONS; MIXED CHIMERISM; IN-VIVO; GRAFT; ALEMTUZUMAB; LEUKEMIA; RELAPSE; IMPACT; RISK;

D O I：

10.1016/j.leukres.2019.106173

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The importance of chimerism status in the very early period after hematopoietic stem cell transplantation is unclear. We determined PBMC and T-cell donor chimerism 50 days after transplantation and related this to disease relapse and overall survival. Methods: 144 sequential patients underwent transplantation of which 90 had AML/MDS and 54 had lymphoma. 'Full donor chimerism' was defined as >= 99% donor cells and three patient groups were defined: 40% with full donor chimerism (FC) in both PBMC and T-cells; 25% with mixed chimerism (MC) within both compartments and 35% with 'split' chimerism (SC) characterised by full donor chimerism within PBMC and mixed chimerism within T-cells. Results: In patients with myeloid disease a pattern of mixed chimerism (MC) was associated with a one year relapse rate of 45% and a five year overall survival of 40% compared to values of 8% and 75%, and 17% and 60%, for those with SC or FC respectively. The pattern of chimerism had no impact on clinical outcome for lymphoma. Conclusion: The pattern of lineage-specific chimerism at 50 days after transplantation is highly predictive of clinical outcome for patients with myeloid malignancy and may help to guide subsequent clinical management.

引用

页数：7

共 42 条

[41] Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT [J].

Tessoulin, B. ;

Delaunay, J. ;

Chevallier, P. ;

Loirat, M. ;

Ayari, S. ;

Peterlin, P. ;

Le Gouill, S. ;

Gastinne, T. ;

Moreau, P. ;

Mohty, M. ;

Guillaume, T. .

BONE MARROW TRANSPLANTATION, 2014, 49 (04) :567-571

[42]

van Besien K., 2015, LEUKEMIA LYMPHOMA, V50, P1809

← 1 2 3 4 5 →